Global Acute Migraine Drugs Market

Acute Migraine Drugs Comprehensive Study by Type (Nonsteroidal Anti-Inflammatory Drugs, Triptans, Dihydroergotamine, Nonspecific Migraine Medications, Analgesics), Application (Hospitals, Clinics, Household Use, Others), Route of Administration (Oral, Injectables, Others), Distribution Channel (Hospital-Based Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2024

Acute Migraine Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Acute Migraine Drugs Market Overview:
A migraine is a severe, recurring and painful headache. Migraine is a neurological disease that is prevalent globally and it is reported that frequent use of some medicines or overdose can also lead to a migraine. According to the Migraine Research Foundation, 17.4% of women are exposed to a migraine as compared to men (6%) due to fluctuation in female reproductive hormones like estrogen and results in a migraine.

Market Drivers
  • Increase in Migraine Prevalence
  • Hectic Lifestyle of the People


Restraints
  • Lack of Proper and Undiagnosed Cases of Migraine
  • Adverse Effects of Drugs of Migraine

Opportunities
  • Demand for Total Cure Medications for Migraine in the Market
  • Increasing Awareness Regarding the Treatment

Challenges
  • Increased Preference for Alternative Drugs


Competitive Landscape:

Some of the key players profiled in the report are Allergan (Ireland), Endo International (Ireland), GlaxoSmithKline (United States), Teva Pharmaceutical Industries (Israel), Novartis AG (Switzerland), Sanofi SA (France), Eli Lilly and Company (United States), Impax Laboratories, LLC (United States), Pfizer (United States), Abbott (United States), Johnson & Johnson (United States), Avanir Pharmaceuticals, Inc. (United States) and Merck & Co. (United States). Additionally, following companies can also be profiled that are part of our coverage like H. Lundbeck A/S (Denmark), Alder BioPharmaceuticals (United States), Amegen (United States) and Dr. Reddy’s Laboratories (India). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Acute Migraine Drugs market by 2024. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Acute Migraine Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital-Based Pharmacies will boost the Acute Migraine Drugs market.

Market Highlights:
In September 2018, A new method of treatment Galcanezumab-gnlm which targets calcitonin gene-related peptide (CGRP), a molecule that's produced in nerve cells of the brain and spinal cord, two other drugs Ernumab and fremanezumab-vfrm approved by FDA. This method may provide long-lasting relief for migraine by blocking the activation of a molecule which is involved in the process of pain.

On 17th May 2018, Novartis and Amgen announced that the United States Food and Drug Administration has approved Erenumab (Aimovig) to prevent migraines in adults.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Acute Migraine Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Acute Migraine Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Healthcare providers, Government agencies, Distributors and Suppliers and Pharmaceutical industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Nonsteroidal Anti-Inflammatory Drugs
  • Triptans
  • Dihydroergotamine
  • Nonspecific Migraine Medications
  • Analgesics
By Application
  • Hospitals
  • Clinics
  • Household Use
  • Others
By Route of Administration
  • Oral
  • Injectables
  • Others

By Distribution Channel
  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Migraine Prevalence
      • 3.2.2. Hectic Lifestyle of the People
    • 3.3. Market Challenges
      • 3.3.1. Increased Preference for Alternative Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acute Migraine Drugs, by Type, Application, Route of Administration, Distribution Channel and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Acute Migraine Drugs (Value)
      • 5.2.1. Global Acute Migraine Drugs by: Type (Value)
        • 5.2.1.1. Nonsteroidal Anti-Inflammatory Drugs
        • 5.2.1.2. Triptans
        • 5.2.1.3. Dihydroergotamine
        • 5.2.1.4. Nonspecific Migraine Medications
        • 5.2.1.5. Analgesics
      • 5.2.2. Global Acute Migraine Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Household Use
        • 5.2.2.4. Others
      • 5.2.3. Global Acute Migraine Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectables
        • 5.2.3.3. Others
      • 5.2.4. Global Acute Migraine Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital-Based Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Acute Migraine Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Acute Migraine Drugs (Volume)
      • 5.3.1. Global Acute Migraine Drugs by: Type (Volume)
        • 5.3.1.1. Nonsteroidal Anti-Inflammatory Drugs
        • 5.3.1.2. Triptans
        • 5.3.1.3. Dihydroergotamine
        • 5.3.1.4. Nonspecific Migraine Medications
        • 5.3.1.5. Analgesics
      • 5.3.2. Global Acute Migraine Drugs by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Household Use
        • 5.3.2.4. Others
      • 5.3.3. Global Acute Migraine Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injectables
        • 5.3.3.3. Others
      • 5.3.4. Global Acute Migraine Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital-Based Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online Pharmacies
      • 5.3.5. Global Acute Migraine Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Acute Migraine Drugs (Price)
      • 5.4.1. Global Acute Migraine Drugs by: Type (Price)
  • 6. Acute Migraine Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Endo International (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Impax Laboratories, LLC (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson & Johnson (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Avanir Pharmaceuticals, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Merck & Co. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Acute Migraine Drugs Sale, by Type, Application, Route of Administration, Distribution Channel and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Acute Migraine Drugs (Value)
      • 7.2.1. Global Acute Migraine Drugs by: Type (Value)
        • 7.2.1.1. Nonsteroidal Anti-Inflammatory Drugs
        • 7.2.1.2. Triptans
        • 7.2.1.3. Dihydroergotamine
        • 7.2.1.4. Nonspecific Migraine Medications
        • 7.2.1.5. Analgesics
      • 7.2.2. Global Acute Migraine Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Household Use
        • 7.2.2.4. Others
      • 7.2.3. Global Acute Migraine Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectables
        • 7.2.3.3. Others
      • 7.2.4. Global Acute Migraine Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital-Based Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Acute Migraine Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Acute Migraine Drugs (Volume)
      • 7.3.1. Global Acute Migraine Drugs by: Type (Volume)
        • 7.3.1.1. Nonsteroidal Anti-Inflammatory Drugs
        • 7.3.1.2. Triptans
        • 7.3.1.3. Dihydroergotamine
        • 7.3.1.4. Nonspecific Migraine Medications
        • 7.3.1.5. Analgesics
      • 7.3.2. Global Acute Migraine Drugs by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Household Use
        • 7.3.2.4. Others
      • 7.3.3. Global Acute Migraine Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injectables
        • 7.3.3.3. Others
      • 7.3.4. Global Acute Migraine Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital-Based Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online Pharmacies
      • 7.3.5. Global Acute Migraine Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Acute Migraine Drugs (Price)
      • 7.4.1. Global Acute Migraine Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acute Migraine Drugs: by Type(USD Million)
  • Table 2. Acute Migraine Drugs Nonsteroidal Anti-Inflammatory Drugs , by Region USD Million (2013-2018)
  • Table 3. Acute Migraine Drugs Triptans , by Region USD Million (2013-2018)
  • Table 4. Acute Migraine Drugs Dihydroergotamine , by Region USD Million (2013-2018)
  • Table 5. Acute Migraine Drugs Nonspecific Migraine Medications , by Region USD Million (2013-2018)
  • Table 6. Acute Migraine Drugs Analgesics , by Region USD Million (2013-2018)
  • Table 7. Acute Migraine Drugs: by Application(USD Million)
  • Table 8. Acute Migraine Drugs Hospitals , by Region USD Million (2013-2018)
  • Table 9. Acute Migraine Drugs Clinics , by Region USD Million (2013-2018)
  • Table 10. Acute Migraine Drugs Household Use , by Region USD Million (2013-2018)
  • Table 11. Acute Migraine Drugs Others , by Region USD Million (2013-2018)
  • Table 12. Acute Migraine Drugs: by Route of Administration(USD Million)
  • Table 13. Acute Migraine Drugs Oral , by Region USD Million (2013-2018)
  • Table 14. Acute Migraine Drugs Injectables , by Region USD Million (2013-2018)
  • Table 15. Acute Migraine Drugs Others , by Region USD Million (2013-2018)
  • Table 16. Acute Migraine Drugs: by Distribution Channel(USD Million)
  • Table 17. Acute Migraine Drugs Hospital-Based Pharmacies , by Region USD Million (2013-2018)
  • Table 18. Acute Migraine Drugs Retail Pharmacies , by Region USD Million (2013-2018)
  • Table 19. Acute Migraine Drugs Online Pharmacies , by Region USD Million (2013-2018)
  • Table 20. South America Acute Migraine Drugs, by Country USD Million (2013-2018)
  • Table 21. South America Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 22. South America Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 23. South America Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 24. South America Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 25. Brazil Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 26. Brazil Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 27. Brazil Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 28. Brazil Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 29. Argentina Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 30. Argentina Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 31. Argentina Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 32. Argentina Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 33. Rest of South America Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 34. Rest of South America Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 35. Rest of South America Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 36. Rest of South America Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 37. Asia Pacific Acute Migraine Drugs, by Country USD Million (2013-2018)
  • Table 38. Asia Pacific Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 39. Asia Pacific Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 40. Asia Pacific Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 41. Asia Pacific Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 42. China Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 43. China Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 44. China Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 45. China Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 46. Japan Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 47. Japan Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 48. Japan Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 49. Japan Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 50. India Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 51. India Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 52. India Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 53. India Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 54. South Korea Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 55. South Korea Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 56. South Korea Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 57. South Korea Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 58. Taiwan Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 59. Taiwan Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 60. Taiwan Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 61. Taiwan Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 62. Australia Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 63. Australia Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 64. Australia Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 65. Australia Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 68. Rest of Asia-Pacific Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 69. Rest of Asia-Pacific Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 70. Europe Acute Migraine Drugs, by Country USD Million (2013-2018)
  • Table 71. Europe Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 72. Europe Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 73. Europe Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 74. Europe Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 75. Germany Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 76. Germany Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 77. Germany Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 78. Germany Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 79. France Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 80. France Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 81. France Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 82. France Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 83. Italy Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 84. Italy Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 85. Italy Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 86. Italy Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 87. United Kingdom Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 88. United Kingdom Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 89. United Kingdom Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 90. United Kingdom Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 91. Netherlands Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 92. Netherlands Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 93. Netherlands Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 94. Netherlands Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 95. Rest of Europe Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 96. Rest of Europe Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 97. Rest of Europe Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 98. Rest of Europe Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 99. MEA Acute Migraine Drugs, by Country USD Million (2013-2018)
  • Table 100. MEA Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 101. MEA Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 102. MEA Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 103. MEA Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 104. Middle East Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 105. Middle East Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 106. Middle East Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 107. Middle East Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 108. Africa Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 109. Africa Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 110. Africa Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 111. Africa Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 112. North America Acute Migraine Drugs, by Country USD Million (2013-2018)
  • Table 113. North America Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 114. North America Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 115. North America Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 116. North America Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 117. United States Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 118. United States Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 119. United States Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 120. United States Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 121. Canada Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 122. Canada Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 123. Canada Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 124. Canada Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 125. Mexico Acute Migraine Drugs, by Type USD Million (2013-2018)
  • Table 126. Mexico Acute Migraine Drugs, by Application USD Million (2013-2018)
  • Table 127. Mexico Acute Migraine Drugs, by Route of Administration USD Million (2013-2018)
  • Table 128. Mexico Acute Migraine Drugs, by Distribution Channel USD Million (2013-2018)
  • Table 129. Acute Migraine Drugs Sales: by Type(K Unit)
  • Table 130. Acute Migraine Drugs Sales Nonsteroidal Anti-Inflammatory Drugs , by Region K Unit (2013-2018)
  • Table 131. Acute Migraine Drugs Sales Triptans , by Region K Unit (2013-2018)
  • Table 132. Acute Migraine Drugs Sales Dihydroergotamine , by Region K Unit (2013-2018)
  • Table 133. Acute Migraine Drugs Sales Nonspecific Migraine Medications , by Region K Unit (2013-2018)
  • Table 134. Acute Migraine Drugs Sales Analgesics , by Region K Unit (2013-2018)
  • Table 135. Acute Migraine Drugs Sales: by Application(K Unit)
  • Table 136. Acute Migraine Drugs Sales Hospitals , by Region K Unit (2013-2018)
  • Table 137. Acute Migraine Drugs Sales Clinics , by Region K Unit (2013-2018)
  • Table 138. Acute Migraine Drugs Sales Household Use , by Region K Unit (2013-2018)
  • Table 139. Acute Migraine Drugs Sales Others , by Region K Unit (2013-2018)
  • Table 140. Acute Migraine Drugs Sales: by Route of Administration(K Unit)
  • Table 141. Acute Migraine Drugs Sales Oral , by Region K Unit (2013-2018)
  • Table 142. Acute Migraine Drugs Sales Injectables , by Region K Unit (2013-2018)
  • Table 143. Acute Migraine Drugs Sales Others , by Region K Unit (2013-2018)
  • Table 144. Acute Migraine Drugs Sales: by Distribution Channel(K Unit)
  • Table 145. Acute Migraine Drugs Sales Hospital-Based Pharmacies , by Region K Unit (2013-2018)
  • Table 146. Acute Migraine Drugs Sales Retail Pharmacies , by Region K Unit (2013-2018)
  • Table 147. Acute Migraine Drugs Sales Online Pharmacies , by Region K Unit (2013-2018)
  • Table 148. South America Acute Migraine Drugs Sales, by Country K Unit (2013-2018)
  • Table 149. South America Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 150. South America Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 151. South America Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 152. South America Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 153. Brazil Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 154. Brazil Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 155. Brazil Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 156. Brazil Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 157. Argentina Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 158. Argentina Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 159. Argentina Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 160. Argentina Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 161. Rest of South America Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 162. Rest of South America Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 163. Rest of South America Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 164. Rest of South America Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 165. Asia Pacific Acute Migraine Drugs Sales, by Country K Unit (2013-2018)
  • Table 166. Asia Pacific Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 167. Asia Pacific Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 168. Asia Pacific Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 169. Asia Pacific Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 170. China Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 171. China Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 172. China Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 173. China Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 174. Japan Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 175. Japan Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 176. Japan Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 177. Japan Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 178. India Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 179. India Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 180. India Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 181. India Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 182. South Korea Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 183. South Korea Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 184. South Korea Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 185. South Korea Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 186. Taiwan Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 187. Taiwan Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 188. Taiwan Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 189. Taiwan Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 190. Australia Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 191. Australia Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 192. Australia Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 193. Australia Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 194. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 195. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 196. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 197. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 198. Europe Acute Migraine Drugs Sales, by Country K Unit (2013-2018)
  • Table 199. Europe Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 200. Europe Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 201. Europe Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 202. Europe Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 203. Germany Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 204. Germany Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 205. Germany Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 206. Germany Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 207. France Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 208. France Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 209. France Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 210. France Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 211. Italy Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 212. Italy Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 213. Italy Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 214. Italy Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 215. United Kingdom Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 216. United Kingdom Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 217. United Kingdom Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 218. United Kingdom Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 219. Netherlands Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 220. Netherlands Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 221. Netherlands Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 222. Netherlands Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 223. Rest of Europe Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 224. Rest of Europe Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 225. Rest of Europe Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 226. Rest of Europe Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 227. MEA Acute Migraine Drugs Sales, by Country K Unit (2013-2018)
  • Table 228. MEA Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 229. MEA Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 230. MEA Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 231. MEA Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 232. Middle East Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 233. Middle East Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 234. Middle East Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 235. Middle East Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 236. Africa Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 237. Africa Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 238. Africa Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 239. Africa Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 240. North America Acute Migraine Drugs Sales, by Country K Unit (2013-2018)
  • Table 241. North America Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 242. North America Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 243. North America Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 244. North America Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 245. United States Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 246. United States Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 247. United States Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 248. United States Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 249. Canada Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 250. Canada Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 251. Canada Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 252. Canada Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 253. Mexico Acute Migraine Drugs Sales, by Type K Unit (2013-2018)
  • Table 254. Mexico Acute Migraine Drugs Sales, by Application K Unit (2013-2018)
  • Table 255. Mexico Acute Migraine Drugs Sales, by Route of Administration K Unit (2013-2018)
  • Table 256. Mexico Acute Migraine Drugs Sales, by Distribution Channel K Unit (2013-2018)
  • Table 257. Acute Migraine Drugs: by Type(USD/Units)
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Acute Migraine Drugs: by Type(USD Million)
  • Table 272. Acute Migraine Drugs Nonsteroidal Anti-Inflammatory Drugs , by Region USD Million (2019-2024)
  • Table 273. Acute Migraine Drugs Triptans , by Region USD Million (2019-2024)
  • Table 274. Acute Migraine Drugs Dihydroergotamine , by Region USD Million (2019-2024)
  • Table 275. Acute Migraine Drugs Nonspecific Migraine Medications , by Region USD Million (2019-2024)
  • Table 276. Acute Migraine Drugs Analgesics , by Region USD Million (2019-2024)
  • Table 277. Acute Migraine Drugs: by Application(USD Million)
  • Table 278. Acute Migraine Drugs Hospitals , by Region USD Million (2019-2024)
  • Table 279. Acute Migraine Drugs Clinics , by Region USD Million (2019-2024)
  • Table 280. Acute Migraine Drugs Household Use , by Region USD Million (2019-2024)
  • Table 281. Acute Migraine Drugs Others , by Region USD Million (2019-2024)
  • Table 282. Acute Migraine Drugs: by Route of Administration(USD Million)
  • Table 283. Acute Migraine Drugs Oral , by Region USD Million (2019-2024)
  • Table 284. Acute Migraine Drugs Injectables , by Region USD Million (2019-2024)
  • Table 285. Acute Migraine Drugs Others , by Region USD Million (2019-2024)
  • Table 286. Acute Migraine Drugs: by Distribution Channel(USD Million)
  • Table 287. Acute Migraine Drugs Hospital-Based Pharmacies , by Region USD Million (2019-2024)
  • Table 288. Acute Migraine Drugs Retail Pharmacies , by Region USD Million (2019-2024)
  • Table 289. Acute Migraine Drugs Online Pharmacies , by Region USD Million (2019-2024)
  • Table 290. South America Acute Migraine Drugs, by Country USD Million (2019-2024)
  • Table 291. South America Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 292. South America Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 293. South America Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 294. South America Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 295. Brazil Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 296. Brazil Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 297. Brazil Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 298. Brazil Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 299. Argentina Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 300. Argentina Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 301. Argentina Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 302. Argentina Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 303. Rest of South America Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 304. Rest of South America Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 305. Rest of South America Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 306. Rest of South America Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 307. Asia Pacific Acute Migraine Drugs, by Country USD Million (2019-2024)
  • Table 308. Asia Pacific Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 309. Asia Pacific Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 310. Asia Pacific Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 311. Asia Pacific Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 312. China Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 313. China Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 314. China Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 315. China Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 316. Japan Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 317. Japan Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 318. Japan Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 319. Japan Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 320. India Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 321. India Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 322. India Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 323. India Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 324. South Korea Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 325. South Korea Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 326. South Korea Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 327. South Korea Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 328. Taiwan Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 329. Taiwan Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 330. Taiwan Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 331. Taiwan Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 332. Australia Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 333. Australia Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 334. Australia Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 335. Australia Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 336. Rest of Asia-Pacific Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 337. Rest of Asia-Pacific Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 338. Rest of Asia-Pacific Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 339. Rest of Asia-Pacific Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 340. Europe Acute Migraine Drugs, by Country USD Million (2019-2024)
  • Table 341. Europe Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 342. Europe Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 343. Europe Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 344. Europe Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 345. Germany Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 346. Germany Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 347. Germany Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 348. Germany Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 349. France Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 350. France Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 351. France Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 352. France Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 353. Italy Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 354. Italy Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 355. Italy Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 356. Italy Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 357. United Kingdom Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 358. United Kingdom Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 359. United Kingdom Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 360. United Kingdom Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 361. Netherlands Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 362. Netherlands Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 363. Netherlands Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 364. Netherlands Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 365. Rest of Europe Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 366. Rest of Europe Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 367. Rest of Europe Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 368. Rest of Europe Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 369. MEA Acute Migraine Drugs, by Country USD Million (2019-2024)
  • Table 370. MEA Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 371. MEA Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 372. MEA Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 373. MEA Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 374. Middle East Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 375. Middle East Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 376. Middle East Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 377. Middle East Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 378. Africa Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 379. Africa Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 380. Africa Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 381. Africa Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 382. North America Acute Migraine Drugs, by Country USD Million (2019-2024)
  • Table 383. North America Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 384. North America Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 385. North America Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 386. North America Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 387. United States Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 388. United States Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 389. United States Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 390. United States Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 391. Canada Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 392. Canada Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 393. Canada Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 394. Canada Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 395. Mexico Acute Migraine Drugs, by Type USD Million (2019-2024)
  • Table 396. Mexico Acute Migraine Drugs, by Application USD Million (2019-2024)
  • Table 397. Mexico Acute Migraine Drugs, by Route of Administration USD Million (2019-2024)
  • Table 398. Mexico Acute Migraine Drugs, by Distribution Channel USD Million (2019-2024)
  • Table 399. Acute Migraine Drugs Sales: by Type(K Unit)
  • Table 400. Acute Migraine Drugs Sales Nonsteroidal Anti-Inflammatory Drugs , by Region K Unit (2019-2024)
  • Table 401. Acute Migraine Drugs Sales Triptans , by Region K Unit (2019-2024)
  • Table 402. Acute Migraine Drugs Sales Dihydroergotamine , by Region K Unit (2019-2024)
  • Table 403. Acute Migraine Drugs Sales Nonspecific Migraine Medications , by Region K Unit (2019-2024)
  • Table 404. Acute Migraine Drugs Sales Analgesics , by Region K Unit (2019-2024)
  • Table 405. Acute Migraine Drugs Sales: by Application(K Unit)
  • Table 406. Acute Migraine Drugs Sales Hospitals , by Region K Unit (2019-2024)
  • Table 407. Acute Migraine Drugs Sales Clinics , by Region K Unit (2019-2024)
  • Table 408. Acute Migraine Drugs Sales Household Use , by Region K Unit (2019-2024)
  • Table 409. Acute Migraine Drugs Sales Others , by Region K Unit (2019-2024)
  • Table 410. Acute Migraine Drugs Sales: by Route of Administration(K Unit)
  • Table 411. Acute Migraine Drugs Sales Oral , by Region K Unit (2019-2024)
  • Table 412. Acute Migraine Drugs Sales Injectables , by Region K Unit (2019-2024)
  • Table 413. Acute Migraine Drugs Sales Others , by Region K Unit (2019-2024)
  • Table 414. Acute Migraine Drugs Sales: by Distribution Channel(K Unit)
  • Table 415. Acute Migraine Drugs Sales Hospital-Based Pharmacies , by Region K Unit (2019-2024)
  • Table 416. Acute Migraine Drugs Sales Retail Pharmacies , by Region K Unit (2019-2024)
  • Table 417. Acute Migraine Drugs Sales Online Pharmacies , by Region K Unit (2019-2024)
  • Table 418. South America Acute Migraine Drugs Sales, by Country K Unit (2019-2024)
  • Table 419. South America Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 420. South America Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 421. South America Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 422. South America Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 423. Brazil Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 424. Brazil Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 425. Brazil Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 426. Brazil Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 427. Argentina Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 428. Argentina Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 429. Argentina Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 430. Argentina Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 431. Rest of South America Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 432. Rest of South America Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 433. Rest of South America Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 434. Rest of South America Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 435. Asia Pacific Acute Migraine Drugs Sales, by Country K Unit (2019-2024)
  • Table 436. Asia Pacific Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 437. Asia Pacific Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 438. Asia Pacific Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 439. Asia Pacific Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 440. China Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 441. China Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 442. China Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 443. China Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 444. Japan Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 445. Japan Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 446. Japan Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 447. Japan Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 448. India Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 449. India Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 450. India Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 451. India Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 452. South Korea Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 453. South Korea Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 454. South Korea Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 455. South Korea Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 456. Taiwan Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 457. Taiwan Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 458. Taiwan Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 459. Taiwan Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 460. Australia Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 461. Australia Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 462. Australia Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 463. Australia Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 464. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 465. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 466. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 467. Rest of Asia-Pacific Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 468. Europe Acute Migraine Drugs Sales, by Country K Unit (2019-2024)
  • Table 469. Europe Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 470. Europe Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 471. Europe Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 472. Europe Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 473. Germany Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 474. Germany Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 475. Germany Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 476. Germany Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 477. France Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 478. France Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 479. France Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 480. France Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 481. Italy Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 482. Italy Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 483. Italy Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 484. Italy Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 485. United Kingdom Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 486. United Kingdom Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 487. United Kingdom Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 488. United Kingdom Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 489. Netherlands Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 490. Netherlands Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 491. Netherlands Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 492. Netherlands Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 493. Rest of Europe Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 494. Rest of Europe Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 495. Rest of Europe Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 496. Rest of Europe Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 497. MEA Acute Migraine Drugs Sales, by Country K Unit (2019-2024)
  • Table 498. MEA Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 499. MEA Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 500. MEA Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 501. MEA Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 502. Middle East Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 503. Middle East Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 504. Middle East Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 505. Middle East Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 506. Africa Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 507. Africa Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 508. Africa Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 509. Africa Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 510. North America Acute Migraine Drugs Sales, by Country K Unit (2019-2024)
  • Table 511. North America Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 512. North America Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 513. North America Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 514. North America Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 515. United States Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 516. United States Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 517. United States Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 518. United States Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 519. Canada Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 520. Canada Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 521. Canada Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 522. Canada Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 523. Mexico Acute Migraine Drugs Sales, by Type K Unit (2019-2024)
  • Table 524. Mexico Acute Migraine Drugs Sales, by Application K Unit (2019-2024)
  • Table 525. Mexico Acute Migraine Drugs Sales, by Route of Administration K Unit (2019-2024)
  • Table 526. Mexico Acute Migraine Drugs Sales, by Distribution Channel K Unit (2019-2024)
  • Table 527. Acute Migraine Drugs: by Type(USD/Units)
  • Table 528. Research Programs/Design for This Report
  • Table 529. Key Data Information from Secondary Sources
  • Table 530. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acute Migraine Drugs: by Type USD Million (2013-2018)
  • Figure 5. Global Acute Migraine Drugs: by Application USD Million (2013-2018)
  • Figure 6. Global Acute Migraine Drugs: by Route of Administration USD Million (2013-2018)
  • Figure 7. Global Acute Migraine Drugs: by Distribution Channel USD Million (2013-2018)
  • Figure 8. South America Acute Migraine Drugs Share (%), by Country
  • Figure 9. Asia Pacific Acute Migraine Drugs Share (%), by Country
  • Figure 10. Europe Acute Migraine Drugs Share (%), by Country
  • Figure 11. MEA Acute Migraine Drugs Share (%), by Country
  • Figure 12. North America Acute Migraine Drugs Share (%), by Country
  • Figure 13. Global Acute Migraine Drugs: by Type K Unit (2013-2018)
  • Figure 14. Global Acute Migraine Drugs: by Application K Unit (2013-2018)
  • Figure 15. Global Acute Migraine Drugs: by Route of Administration K Unit (2013-2018)
  • Figure 16. Global Acute Migraine Drugs: by Distribution Channel K Unit (2013-2018)
  • Figure 17. South America Acute Migraine Drugs Share (%), by Country
  • Figure 18. Asia Pacific Acute Migraine Drugs Share (%), by Country
  • Figure 19. Europe Acute Migraine Drugs Share (%), by Country
  • Figure 20. MEA Acute Migraine Drugs Share (%), by Country
  • Figure 21. North America Acute Migraine Drugs Share (%), by Country
  • Figure 22. Global Acute Migraine Drugs: by Type USD/Units (2013-2018)
  • Figure 23. Global Acute Migraine Drugs share by Players 2018 (%)
  • Figure 24. Global Acute Migraine Drugs share by Players (Top 3) 2018(%)
  • Figure 25. Global Acute Migraine Drugs share by Players (Top 5) 2018(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. Allergan (Ireland) Revenue: by Geography 2018
  • Figure 29. Endo International (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Endo International (Ireland) Revenue: by Geography 2018
  • Figure 31. GlaxoSmithKline (United States) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline (United States) Revenue: by Geography 2018
  • Figure 33. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2018
  • Figure 35. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 37. Sanofi SA (France) Revenue, Net Income and Gross profit
  • Figure 38. Sanofi SA (France) Revenue: by Geography 2018
  • Figure 39. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 40. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 41. Impax Laboratories, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 42. Impax Laboratories, LLC (United States) Revenue: by Geography 2018
  • Figure 43. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer (United States) Revenue: by Geography 2018
  • Figure 45. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 46. Abbott (United States) Revenue: by Geography 2018
  • Figure 47. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 48. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 49. Avanir Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 50. Avanir Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 51. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 52. Merck & Co. (United States) Revenue: by Geography 2018
  • Figure 53. Global Acute Migraine Drugs: by Type USD Million (2019-2024)
  • Figure 54. Global Acute Migraine Drugs: by Application USD Million (2019-2024)
  • Figure 55. Global Acute Migraine Drugs: by Route of Administration USD Million (2019-2024)
  • Figure 56. Global Acute Migraine Drugs: by Distribution Channel USD Million (2019-2024)
  • Figure 57. South America Acute Migraine Drugs Share (%), by Country
  • Figure 58. Asia Pacific Acute Migraine Drugs Share (%), by Country
  • Figure 59. Europe Acute Migraine Drugs Share (%), by Country
  • Figure 60. MEA Acute Migraine Drugs Share (%), by Country
  • Figure 61. North America Acute Migraine Drugs Share (%), by Country
  • Figure 62. Global Acute Migraine Drugs: by Type K Unit (2019-2024)
  • Figure 63. Global Acute Migraine Drugs: by Application K Unit (2019-2024)
  • Figure 64. Global Acute Migraine Drugs: by Route of Administration K Unit (2019-2024)
  • Figure 65. Global Acute Migraine Drugs: by Distribution Channel K Unit (2019-2024)
  • Figure 66. South America Acute Migraine Drugs Share (%), by Country
  • Figure 67. Asia Pacific Acute Migraine Drugs Share (%), by Country
  • Figure 68. Europe Acute Migraine Drugs Share (%), by Country
  • Figure 69. MEA Acute Migraine Drugs Share (%), by Country
  • Figure 70. North America Acute Migraine Drugs Share (%), by Country
  • Figure 71. Global Acute Migraine Drugs: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Allergan (Ireland)
  • Endo International (Ireland)
  • GlaxoSmithKline (United States)
  • Teva Pharmaceutical Industries (Israel)
  • Novartis AG (Switzerland)
  • Sanofi SA (France)
  • Eli Lilly and Company (United States)
  • Impax Laboratories, LLC (United States)
  • Pfizer (United States)
  • Abbott (United States)
  • Johnson & Johnson (United States)
  • Avanir Pharmaceuticals, Inc. (United States)
  • Merck & Co. (United States)
Additional players considered in the study are as follows:
H. Lundbeck A/S (Denmark) , Alder BioPharmaceuticals (United States) , Amegen (United States) , Dr. Reddy’s Laboratories (India) , ,
Select User Access Type

Key Highlights of Report


Apr 2020 247 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acute Migraine Drugs Market Quantitative research analysis
Global Acute Migraine Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Acute Migraine Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Tardive Dyskinesia Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), Treatment (Dopamine-Depleting Medications, GABA Receptor Agonist Medications, Antic...
$ 3450
Chemotherapy-Induced Nausea and Vomiting (CINV) Comprehensive Study by Type (CINV, PONV), Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), Patient Pool Type (Aloxi, Kytril, E...
$ 3450
Erythropoietin Drugs Comprehensive Study by Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), Application (Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis), Others (...
$ 3450
Diaper Rash Cream Comprehensive Study by Type (Zinc Oxide-based, Zinc Oxide Free), Application (Hospitals and Clinics, Personal Care, Other), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy...
$ 3650
Pig Vaccine Comprehensive Study by Application (Veterinary Hospitals, Hog Production Farms), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjuga...
$ 3750
Intravenous Immunoglobulin (IVIg) Comprehensive Study by Type (Gammagard S/D, Gammagard Liquid, Gamunex, IGIVnex, Privigen, Others), Application (Neurology, Haematology, Immunology, Dermatology, Othe...
$ 3450